However, only part of the AML cases is characterized by the NPM1 mutation and because MFC enables the analysis of MRD in the vast majority (>90%) of AML cases for the best prediction of an AML relapse, at present both NPM1‐MRD and MFC‐MRD are necessary (Zeijlemaker et al., 2019). This evidence concerns the gene NPM1 and acute myeloid leukemia.